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Conclusion: A Mediterranean diet is an effective method of primary
prevention for coronary heart disease.
Summary: There is an increase in longevity and a lower incidence of
vascular disease associated morbidity and mortality in southern compared
with northern Europe in the Seven Country Study and in the Monitoring of
Trends and Determinants in Cardiovascular Diseases (MONICA) survey
(Am J Epidemiol 1986;124:903-15 and Lancet 1999;353:1547-57). A
Mediterranean diet score as been developed to investigate the health effects
of Mediterranean diets. The key features of a Mediterranean diet are high
consumption of olive oil and plant-based foods, such as fruit, vegetables,
legumes, whole-grain cereals, nuts, and seeds, with moderate-to-high con-
sumption of fish, moderate consumption of alcohol (particularly red wine)
and dairy products, and relatively low consumption of meat (especially red
meat). The data suggest a 2-point increase in theMediterranean diet score is
associated with a 9% reduced risk of mortality from cardiovascular disease
(N Engl J Med 2003;343:2599-608).
Most studies in this field have been case-controlled studies that have
focused on individuals with known cardiovascular disease and have examined
secondary preventive effects of a Mediterranean diet. Nutritional factors
related to secondary prevention of vascular disease may not be the same as
those related to primary prevention. The purpose of this study was to
investigate, in a prospective fashion, the relationship between adherence to a
relative Mediterranean diet and incident coronary events, focusing on pri-
mary prevention. The study focused on patients from five Spanish centers of
the European Prospective Investigation into Cancer (EPIC) and Nutrition
Study. Data were analyzed from 41,078 participants aged 29 to 69 years
recruited from 1992 to 1996. They were followed-up until December 2004
for a median of 10.4 years. The incidence of fatal and nonfatal coronary heart
disease events was analyzed according to adherence to a Mediterranean diet.
This was measured by using an 18-unit relative Mediterranean diet score.
Of the study participants, 609 (79% male) had a confirmed fatal or
nonfatal acute myocardial infarction (n 468) or unstable angina requiring
revascularization (n  141). Adjusting for age, center, and recognized
coronary heart disease risk factors, a high compared with low relative
Mediterranean diet score was associated with a significant reduction in
coronary heart disease risk (hazard ratio, 0.6; 95% confidence interval,
0.47-0.77). A 1-unit increase in the relative Mediterranean diet score was
associated with a 6% reduced risk of coronary heart disease (95% confidence
interval, 0.91-0.97).
Comment:The results of this study add to the existing literature on the
health benefits of a Mediterranean diet by providing evidence of the impor-
tance of aMediterranean diet in the primary prevention of coronary events in
healthy individuals. Which components of the Mediterranean diet are most
important in providing primary cardioprotective effects are unknown. Sort-
ing out the individual effects of the Mediterranean diet, and whether the
health benefits also translate to the peripheral arteries, will likely be an
important future focus of this type of epidemiologic research.
Carotid Artery Stenting Compared with Endarterectomy in Patients
with Symptomatic Carotid Stenosis (International Carotid Stenting
Study): An Interim Analysis of a Randomised Controlled Trial
International Carotid Stenting Study Investigators. Lancet 2010;375:985-97.
Conclusion: In patients with symptomatic internal carotid artery
(ICA) stenosis who are suitable for surgery, carotid endarterectomy, at the
present time, should remain the treatment of choice.
Summary:Carotid artery stents have emerged as an alternative treatment
to endarterectomy for selected patients with asymptomatic and symptomatic
ICA stenosis. Previous randomized, controlled, government-sponsored trials
have failed to establish equivalency of the safety and efficacy of carotid artery
stenting to endarterectomy in symptomatic patients. Patients in the Stent-
Protected Angioplasty versus Carotid Endarterectomy trial (SPACE) did not
show noninferiority of stenting compared with endarterectomy within 30
days of treatment. The trial was stopped early for statistical reasons of futility
and for costs (Lancet 2006;368:1239-47). Another European trial, The
Endarterectomy versus Stenting in Patients with Symptomatic Severe Ca-
rotid Stenosis (EVA-3S) trial, was also stopped early because of higher
periprocedural stroke and death rates in the stenting group (N Engl
J Med 2006;355:1660-71).
1320In this study, the authors report results of the International Carotid
Stenting Study (ICSS). ICSS is a multicenter, international, randomized,
controlled trial of carotid endarterectomy vs stenting in patients with re-
cently symptomatic carotid artery stenosis. Recent symptomswere defined as
amaurosis fugax, transient ischemic attacks, ipsilateral hemispheric stroke, or
retinal infarction occurring within the previous year (95% of the patients in
the study were randomized within 6 months of their symptomatic event).
The study used blinded adjudication of outcomes, and patients were as-
signed in a randomized fashion to receive a 1:1 ratio of carotid artery
stenting or endarterectomy. Each center was stratified for sex, age, contralat-
eral occlusion, and side of randomized artery. Physicians not involved in the
randomized treatment provided the follow-up. The study is designed with a
primary end point of fatal or nondisabling stroke in any territory at 3 years.
The current article represents an interim safety analysis of 120-day rate of
stroke, death, or procedural myocardial infarction. Analysis was performed
on an intention-to-treat basis and on a per-protocol basis.
The trial enrolled 1713 patients, consisting of 858 in the endarterec-
tomy group and 855 in the stenting group. Between randomization and 120
days, there were 34 events of disabling stoke or death in the stenting group
(4% by Kaplan-Meier estimate) and 27 in the endarterectomy group (3.2%
by Kaplan-Meier estimate; hazard ratio [HR], 1.28; 95% confidence interval
[CI], 0.77-2.11). The occurrence of any stoke, death, or myocardial infarc-
tion in the stenting group was 8.5% vs 5.2% in the endarterectomy group (72
vs 44 events; HR, 1.69; 95% CI, 1.16-2.45; P  .006). Risk of any stroke
(65 vs 35 events; HR, 1.92; 95% CI, 1.27-2.89) and all cause death (19 vs 7
events; HR, 2.76; 95% CI, 1.16-6.56) were higher in the stenting group
than in the endarterectomy group. Of the seven peri-procedural myocardial
infarctions that were recorded, three were in the stenting group and all were
fatal; four were in the endarterectomy group, and none were fatal. There
were 45 cranial nerve palsies in the endarterectomy group and one in the
stenting group. There were 31 significant hematomas in the stenting group
vs 50 in the endarterectomy group (P  .0197).
Comment: This study was released online to coincide with presenta-
tion of the Carotid Revascularization Endarterectomy Versus Stenting Trial
(CREST) data at the recent stroke meetings in San Antonio. The CREST
manuscript at the time of this writing is currently under review and not
available for analysis. However, it is safe to say that the results of ICSS and
CREST, while conflicting in some respects, are similar in others. These
similarities and differences will provide fodder for comments and discussion
for a considerable period. All of us involved in the treatment of patients with
symptomatic carotid stenosis will have to evaluate the preponderance of data
that is available to help us decide how to treat our patients with symptomatic
carotid stenosis. Although it is quite clear that the European data taken as a
whole favor endarterectomy over stenting for patients with symptomatic
carotid stenosis, the differences in the short-term are not so great that
patients presented with options in an appropriate and unbiased manner can
reasonably choose either procedure. Physicians, however, must make rec-
ommendations, and it will be up to each treating physician to make respon-
sible recommendations to individual patients, independent of financial con-
siderations.
Carotid Endarterectomy Benefits Patients with CKD and Symptomatic
High-Grade Stenosis
Mathew A, Eliasziw M, Dvereaux PJ, et al; for the North American Symp-
tomatic Carotid Endarterectomy Trial (nascet) Collaborators. J Am Soc
Nephrol 2010;21:145-52.
Conclusion: Patients with stage 3 chronic kidney disease (CKD) and
symptomatic high-grade carotid stenosis have a marked benefit in stroke risk
reduction after carotid endarterectomy.
Summary: Approximately 800,000 people in North America have a
stroke each year, and nearly 200,000 of these are recurrent strokes (Circu-
lation 2009;119:e21-181). More than 15 million Americans have CKD,
with an increasing prevalence (JAMA 2007;298:2038-47). Patients with
CKD in some cases are more prone to adverse events complicating proce-
dures and treatments. In other situations, however, patients with CKD
derive larger absolute benefits because of higher baseline risk. The North
American Symptomatic Carotid Endarterectomy Trial (NASCET) collected
baseline levels of serum creatinine for all trial participants. The aim of this
study was to examine outcomes of patients with and without CKD enrolled
in NASCET.
Patients in this reanalysis included those with symptomatic stenosis and
either stage 3 CKD (n  524; estimated glomerular filtration rate [GFR]
260 mL/min/1.73 m ) or preserved kidney function (n  966; estimated
GFR60mL/min/1.73m2). GFR was determined using theModification
